Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2024-02-21 Regulatory Filings
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Appendix 4E and 2023 Annual Report 181 pages 21.8MB
Regulatory Filings
2024-02-21 English
2023 Full Year Results Release 3 pages 132.3KB
Annual Report Classification · 95% confidence The document is titled 'RESULTS ANNOUNCEMENT' and is an ASX release dated 22 February 2024, presenting the full year financial results for the fiscal year ended 31 December 2023. It includes detailed financial performance data such as revenue, EBITDA, net profit, cash flow, and operational highlights. The document also discusses pipeline progress, regulatory submissions, and future guidance. It references the 2023 Annual Report and an accompanying investor presentation as separate documents. The length of the document (12,295 characters) and the inclusion of substantive financial data and analysis confirm it is a comprehensive financial report rather than a brief announcement or a certification. The content aligns with a full year financial report covering company activity and full financial performance, which fits the definition of an Annual Report (10-K). Although it is called a 'Results Announcement,' the depth and breadth of financial and operational information provided indicate it is the actual report of the full year results, not merely an earnings release or a report publication announcement. Therefore, the appropriate classification is Annual Report (10-K). FY 2023
2024-02-21 English
2023 Full Year Results Presentation 25 pages 1.5MB
Annual Report Classification · 95% confidence The document is titled '2023 Full Year Results Telix Pharmaceuticals' and dated 22 February 2024, indicating it covers a full fiscal year. It contains detailed financial metrics such as revenue growth, profit and loss statements, operating cash flow, adjusted EBITDA, and segment commentary. The content includes comprehensive financial data and analysis for the full year 2023, not just highlights or a brief summary. There is no indication that this is a mere announcement or presentation; rather, it provides substantive financial results and operational commentary. Therefore, this document fits the definition of an Annual Report (10-K equivalent) or a full year financial report. Given the detailed financial data and full year coverage, the best classification is Annual Report (10-K). FY 2023
2024-02-21 English
Appendix 4G and 2023 Corporate Governance Statement 31 pages 2.3MB
Regulatory Filings
2024-02-21 English
Application for quotation of securities - TLX 6 pages 18.5KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) announcement for the application for quotation of securities. It details the issuance and quotation of new securities resulting from options exercised or convertible securities converted. The document includes specifics such as the number of securities, issue dates, and whether the securities are part of an employee incentive scheme. This type of filing is related to changes in the company's capital structure, specifically the issuance and quotation of new shares. It is not a financial report, earnings release, or management discussion, but rather a formal announcement of a capital change. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and content confirm it is not merely an announcement of a report but a substantive filing about securities quotation.
2024-02-08 English
Cleansing Notice 1 page 149.0KB
Regulatory Filings Classification · 95% confidence The document is a notice under section 708A(5)(e) of the Corporations Act 2001 regarding the issue of fully paid ordinary shares upon exercise of unlisted share options. It references an Appendix 2A and confirms compliance with disclosure provisions. The content is about share issuance and compliance notice rather than a full financial report or detailed capital update. The document length is short (1431 characters) and it serves as a formal regulatory announcement about share issuance without substantive financial data or analysis. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories like Capital/Financing Update or Share Issue/Capital Change, since it is a statutory notice under the Corporations Act rather than a direct capital change announcement or financing update.
2024-02-08 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.